| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Silver NanoParticles (AgNPs) Summary: 1.Smaller sizes are generally more bioactive due to increased surface area and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect. 2.Two relevant forms: particulate silver (AgNPs) and ionic silver (Ag⁺). There is debate regarding oral use, as Ag⁺ can precipitate as AgCl in gastric acid, reducing bioavailability; AgNPs may partially avoid this via particulate uptake and intracellular Ag⁺ release. Gastric pH may influence this equilibrium. 3. Dose example 80kg person: 1.12-2mg/day, which can be calculated based on ppm and volume taken (see below) target < 10ppm and 120mL per day (30ppm and 1L per day caused argyria 30mg/day ) (Case Report: 9‐15 ppm@120mL, i.e. 1.1mg/L to 1.8mg/L per day) Likely 10ppm --> 10mg/L, hence if take 100mL, then 1mg/day? (for Cancer) The current Rfd for oral silver exposure is 5 ug/kg/d with a critical dose estimated at 14 ug/kg/d for the average person. Seems like the Cancer target range is 14ug/kg/day to 25ug/kg/day. 80Kg example: 1.12mg to 2mg “1.4µg/kg body weight. If I would have 70kg, I would want to use 100µg/day. However, for fighting active disease, I would tend to explore higher daily dose, as I think this may be too low.” These values reflect experimental or anecdotal contexts and are not established safe or therapeutic doses. 4. Antioxidants such as NAC can counteract AgNP cytotoxicity by restoring glutathione pools and suppressing ROS-mediated mitochondrial damage. 5. In vitro studies commonly show ROS elevation in both cancer and normal cells; however, in vivo, superior antioxidant, NRF2, and repair capacity in normal tissues may confer selectivity. 6. Pathways/mechanisms of action/: -” intracellular ROS was increased...reduction in levels of glutathione (GSH)” - Normal-cell selectivity is partly mediated by NRF2-dependent antioxidant and detoxification responses. - AgNPs impair mitochondrial electron transport, increasing electron leak and amplifying ROS upstream of ΔΨm collapse. -AgNPs inhibit VEGF-driven endothelial signaling and permeability (anti-angiogenic effect) -”upregulation of proapoptotic genes (p53, p21, Bax, and caspases) and downregulation of antiapoptotic genes (Bcl-2)” -” upregulation of AMPK and downregulation of mTOR, MMP-9, BCL-2, and α-SMA” -”p53 is a key player...proapoptotic genes p53 and Bax were significantly increased... noticeable reduction in Bcl-2 transcript levels” -” p53 participates directly in the intrinsic apoptosis pathway by regulating the mitochondrial outer membrane permeabilization” - “Proapoptotic markers (BAX/BCL-XL, cleaved poly(ADP-ribose) polymerase, p53, p21, and caspases 3, 8 and 9) increased.” -”The antiapoptotic markers, AKT and NF-kB, decreased in AgNP-treated cells.” Chronic accumulation and long-term systemic effects remain insufficiently characterized. Silver NanoParticles and Magnetic Fields Summary: 1. “exposure to PMF increased the ability of AgNPs uptake” 2. 6x improvement from AgNPs alone could glucose capping of SilverNPs work as trojan horse? Sodium selenite might protect against toxicity of AgNPs in normal cells. -uncoated AgNPs can degrade the gut microbiome. PVP, citrate, green-synthesized, chitosan coating, may reduce the effect. Similar oxidative considerations may apply to selenium compounds, though mechanisms differ. co-ingestion with food (higher pH) favors reduction and lower Ag+ levels. -action mechanisms of AgNPs: the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure. AgNP anticancer effects come from three overlapping mechanisms: -Nanoparticle–cell interaction (uptake, membrane effects) -Intracellular ROS generation -Controlled Ag⁺ release inside cancer cells
Comparison adding Citrate Capping
| Property | Uncapped AgNPs | Citrate-capped AgNPs |
| --------------------- | -------------- | -------------------- |
| Stability | Poor | Excellent |
| Free Ag⁺ | High | Low |
| Normal cell toxicity | Higher | Lower |
| Cancer selectivity | Lower | **Higher** |
| Mechanism specificity | Crude | **Targeted** |
| Storage behavior | Degrades | Stable |
|
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 4573- | AgNPs, | Bioactive silver nanoparticles derived from Carica papaya floral extract and its dual-functioning biomedical application |
| - | in-vitro, | Var, | MCF-7 | - | NA, | NA, | HEK293 |
| 4584- | AgNPs, | Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 4561- | AgNPs, | VitC, | Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | HEK293 |
| 4558- | AgNPs, | Role of Oxidative and Nitro-Oxidative Damage in Silver Nanoparticles Cytotoxic Effect against Human Pancreatic Ductal Adenocarcinoma Cells |
| - | in-vitro, | PC, | PANC1 |
| 4555- | AgNPs, | Silver nanoparticles from Dendropanax morbifera Léveille inhibit cell migration, induce apoptosis, and increase generation of reactive oxygen species in A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 5977- | AgNPs, | CDT, | Silver Nitroprusside as an Efficient Chemodynamic Therapeutic Agent and a Peroxynitrite nanogenerator for Targeted Cancer Therapy |
| - | in-vivo, | Ovarian, | A2780S | - | NA, | Ovarian, | SKOV3 |
| 5236- | AgNPs, | Adaptive regulations of Nrf2 alleviates silver nanoparticles-induced oxidative stress-related liver cells injury |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| 5147- | AgNPs, | Size dependent anti-invasiveness of silver nanoparticles in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 5145- | AgNPs, | Silver nanoparticles induce irremediable endoplasmic reticulum stress leading to unfolded protein response dependent apoptosis in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 4411- | AgNPs, | Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 4422- | AgNPs, | Bioengineering of Piper longum L. extract mediated silver nanoparticles and their potential biomedical applications |
| - | in-vitro, | Cerv, | HeLa |
| 4421- | AgNPs, | Effect of Biologically Synthesized Silver Nanoparticles on Human Cancer Cells |
| - | in-vitro, | Cerv, | NA |
| 4413- | AgNPs, | Anzaroot, | Green synthesis of silver nanoparticles from plant Astragalus fasciculifolius Bioss and evaluating cytotoxic effects on MCF7 human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4410- | AgNPs, | Green-synthesized silver nanoparticles: a sustainable nanoplatform for targeted colon cancer therapy |
| - | Review, | Colon, | NA |
| 4403- | AgNPs, | Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | GL26 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | RKO |
| 4402- | AgNPs, | Enhancement of Triple-Negative Breast Cancer-Specific Induction of Cell Death by Silver Nanoparticles by Combined Treatment with Proteotoxic Stress Response Inhibitors |
| - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4400- | AgNPs, | Rad, | Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | BC, | MDA-MB-231 |
| 4397- | AgNPs, | Synthesis and Characterization of Silver Nanoparticles from Rhizophora apiculata and Studies on Their Wound Healing, Antioxidant, Anti-Inflammatory, and Cytotoxic Activity |
| - | NA, | Wounds, | NA |
| 4541- | AgNPs, | RosA, | Eco-friendly synthesis of silver nanoparticles: multifaceted antioxidant, antidiabetic, anticancer, and antimicrobial activities |
| - | in-vitro, | Nor, | WI38 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | PC, | PANC1 |
| 4540- | AgNPs, | VitC, | Silver nanoparticles from ascorbic acid: Biosynthesis, characterization, in vitro safety profile, antimicrobial activity and phytotoxicity |
| - | in-vitro, | Nor, | NA |
| 4435- | AgNPs, | Gluc, | Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 4433- | AgNPs, | Advancements in metal and metal oxide nanoparticles for targeted cancer therapy and imaging: Mechanisms, applications, and safety concerns |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| 4431- | AgNPs, | doxoR, | Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | 3T3 |
| 4429- | AgNPs, | Comparative proteomic analysis reveals the different hepatotoxic mechanisms of human hepatocytes exposed to silver nanoparticles |
| - | in-vitro, | Liver, | HepG2 |
| 4388- | AgNPs, | Differential Cytotoxic Potential of Silver Nanoparticles in Human Ovarian Cancer Cells and Ovarian Cancer Stem Cells |
| - | in-vitro, | Cerv, | NA |
| 4363- | AgNPs, | Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma |
| - | in-vivo, | fibroS, | NA |
| 4364- | AgNPs, | Selective cytotoxicity of green synthesized silver nanoparticles against the MCF-7 tumor cell line and their enhanced antioxidant and antimicrobial properties |
| - | in-vitro, | BC, | MCF-7 |
| 4365- | AgNPs, | Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview |
| - | Review, | Var, | NA |
| 4371- | AgNPs, | Effects of Green Silver Nanoparticles on Apoptosis and Oxidative Stress in Normal and Cancerous Human Hepatic Cells in vitro |
| - | in-vitro, | Liver, | HUH7 |
| 4376- | AgNPs, | Interaction of multi-functional silver nanoparticles with living cells |
| - | in-vitro, | Nor, | L929 | - | in-vitro, | Lung, | A549 |
| 375- | AgNPs, | ALA, | Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 2833- | FIS, | AgNPs, | Glucose-capped fisetin silver nanoparticles induced cytotoxicity and ferroptosis in breast cancer cells: A molecular perspective |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1904- | GoldNP, | AgNPs, | Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis |
| - | in-vitro, | Lung, | H157 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Colon, | HCT15 | - | in-vitro, | Melanoma, | A375 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:153 Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid